Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $376,236.90 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Supernus Pharmaceuticals Trading Down 1.2 %

Supernus Pharmaceuticals stock opened at $38.40 on Friday. The company has a market capitalization of $2.12 billion, a P/E ratio of 35.89 and a beta of 0.90. The firm’s fifty day simple moving average is $37.36 and its 200-day simple moving average is $34.78. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SUPN. Millennium Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 395.1% during the 2nd quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock valued at $4,316,000 after purchasing an additional 128,743 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Supernus Pharmaceuticals by 7.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock valued at $710,000 after purchasing an additional 1,870 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $1,070,000. GAMMA Investing LLC raised its holdings in shares of Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares in the last quarter. Finally, Exchange Traded Concepts LLC acquired a new position in Supernus Pharmaceuticals in the 3rd quarter valued at $672,000.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SUPN. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price for the company.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.